{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:49:42Z","timestamp":1791586182748,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Respiratory syncytial virus (RSV) is a major cause of acute respiratory tract infections in young children worldwide. Acute otitis media (AOM) is among the most frequent complications of RSV infection and the leading indication for antibiotic prescribing in this age group. The aim of this study was to evaluate the effectiveness of nirsevimab in reducing the incidence of AOM among infants. We conducted a nationwide register-based interrupted time-series study using data on live births, laboratory-confirmed RSV detections, and AOM diagnoses from four consecutive RSV seasons (2022\u20132023 to 2025\u20132026). Monthly infant populations at risk were reconstructed from birth cohorts to estimate incidence rates during the peak RSV seasons (December\u2013March) which were compared between two pre-implementation and two post-implementation RSV seasons in infants aged\u2009&lt;\u200912 months, stratified into age groups of 0\u20132, 3\u20135, and 6\u201311 months. The study population consisted of 181,999 infants and the follow-up consisted of 2,022,261 infant-months. A total of 3699 RSV-positive findings and 15,830 AOM diagnoses were included in the primary analysis. Following nirsevimab implementation, the incidence of AOM and RSV among infants aged\u2009&lt;\u200912 months decreased by 44% (RR 0.56, 95% CI 0.54\u20130.58) and 83% (RR 0.17, 95% CI 0.15\u20130.18), respectively. The reduction was greatest in the youngest age (0\u20132 months) group.<\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    :\u00a0Implementation of a nirsevimab immunisation programme was associated with a substantial reduction in AOM incidence among infants aged\u2009&lt;\u200912 months, suggesting that RSV immunisation may reduce the burden of AOM in early childhood.\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td align=\"left\" colspan=\"2\">\n                              <jats:bold>What's Known<\/jats:bold>\n                              :\u2022\n                              <jats:italic>RSV is a major cause of morbidity during infancy, and acute otitis media is among its most frequent complications.<\/jats:italic>\n                              \u2022\n                              <jats:italic>Nirsevimab has demonstrated high efficacy in preventing severe RSV disease in young children; however, its effect on outpatient RSV-related complications has not been well established.<\/jats:italic>\n                              <jats:bold>What is New:<\/jats:bold>\n                              \u2022\n                              <jats:italic>This study provides population-based real-world evidence on the impact of nirsevimab on acute otitis media.<\/jats:italic>\n                              \u2022\n                              <jats:italic>Following the implementation of nirsevimab prophylaxis, the incidence of acute otitis media among infants decreased significantly.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-026-07508-y","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:10:41Z","timestamp":1791583841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nirsevimab reduced acute otitis media infections in infants\u2014a nationwide interrupted time-series analysis"],"prefix":"10.1007","volume":"185","author":[{"given":"Niko","family":"Leskinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjo","family":"Renko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilari","family":"Kuitunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"1","key":"7508_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-020-01475-y","volume":"18","author":"G Zhu","year":"2021","unstructured":"Zhu G, Xu D, Zhang Y, Wang T, Zhang L, Gu W et al (2021) Epidemiological characteristics of four common respiratory viral infections in children. Virol J 18(1):10. https:\/\/doi.org\/10.1186\/s12985-020-01475-y","journal-title":"Virol J"},{"issue":"10340","key":"7508_CR2","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2019","unstructured":"Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ et al (2019) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399(10340):2047\u20132064. https:\/\/doi.org\/10.1016\/S0140-6736(22)00478-0","journal-title":"Lancet"},{"issue":"10458","key":"7508_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S0140-6736(24)01716-1","volume":"404","author":"NI Mazur","year":"2024","unstructured":"Mazur NI, Caballero MT, Nunes MC (2024) Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies. Lancet 404(10458):1143\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(24)01716-1","journal-title":"Lancet"},{"issue":"2","key":"7508_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2213-2600(24)00367-9","volume":"13","author":"SF Hak","year":"2021","unstructured":"Hak SF, Sankatsing VDV, Wildenbeest JG, Venekamp RP, Casini B, Rizzo C et al (2021) Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021\u201323). Lancet Respir Med 13(2):153\u2013165. https:\/\/doi.org\/10.1016\/S2213-2600(24)00367-9","journal-title":"Lancet Respir Med"},{"issue":"S1","key":"7508_CR5","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1002\/ppul.27310","volume":"60","author":"HJ Zar","year":"2025","unstructured":"Zar HJ (2025) New advances in RSV: is prevention attainable? Pediatr Pulmonol 60(S1):S120\u2013S122. https:\/\/doi.org\/10.1002\/ppul.27310","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"7508_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, Cots MB, Bosheva M, Madhi SA et al (2022) Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 386(9):837\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2110275","journal-title":"N Engl J Med"},{"issue":"16","key":"7508_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, Sim\u00f5es EAF, Pahud BA, Llapur C et al (2023) Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 388(16):1451\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2216480","journal-title":"N Engl J Med"},{"issue":"13","key":"7508_CR8","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","volume":"393","author":"HJ Zar","year":"2025","unstructured":"Zar HJ, Sim\u00f5es EAF, Madhi SA, Ramilo O, Senders SD, Shepard JS et al (2025) Clesrovimab for prevention of RSV disease in healthy infants. N Engl J Med 393(13):1292\u2013303. https:\/\/doi.org\/10.1056\/NEJMoa2502984","journal-title":"N Engl J Med"},{"issue":"7","key":"7508_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S2352-4642(26)00075-1","volume":"10","author":"Z Valtuille","year":"2026","unstructured":"Valtuille Z, Fafi I, Kaguelidou F, Levy C, Cohen R, Mandelbrot L et al (2026) Effectiveness of nirsevimab immunisation after birth versus RSVpreF maternal vaccination in preventing RSV-related hospitalisations in infants: a population-based retrospective cohort study. Lancet Child Adolesc Health 10(7):481\u2013490. https:\/\/doi.org\/10.1016\/S2352-4642(26)00075-1","journal-title":"Lancet Child Adolesc Health"},{"key":"7508_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103281","author":"D Trusinska","year":"2025","unstructured":"Trusinska D, Lee B, Ferdous S, Kwok HHY, Gordon B, Gao J et al (2025) Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis. eClinicalMedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103281","journal-title":"eClinicalMedicine"},{"issue":"1","key":"7508_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2521912","volume":"21","author":"AC Langedijk","year":"2025","unstructured":"Langedijk AC, van den Dungen F, Harteveld L, van den Boer J, Smit L, Averin A et al (2025) Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands. Hum Vaccin Immunother 21(1):2521912. https:\/\/doi.org\/10.1080\/21645515.2025.2521912","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"7508_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/infdis\/jiaa754","volume":"223","author":"E Thomas","year":"2021","unstructured":"Thomas E, Mattila JM, Lehtinen P, Vuorinen T, Waris M, Heikkinen T (2021) Burden of respiratory syncytial virus infection during the first year of life. J Infect Dis 223(5):811\u20137. https:\/\/doi.org\/10.1093\/infdis\/jiaa754","journal-title":"J Infect Dis"},{"issue":"6","key":"7508_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/s0022-3476(05)81950-x","volume":"120","author":"T Chonmaitree","year":"1992","unstructured":"Chonmaitree T, Owen MJ, Patel JA, Hedgpeth D, Horlick D, Howie VM (1992) Effect of viral respiratory tract infection on outcome of acute otitis media. J Pediatr 120(6):856\u201362. https:\/\/doi.org\/10.1016\/s0022-3476(05)81950-x","journal-title":"J Pediatr"},{"issue":"3","key":"7508_CR14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-0181","volume":"140","author":"R Kaur","year":"2017","unstructured":"Kaur R, Morris M, Pichichero ME (2017) Epidemiology of acute otitis media in the postpneumococcal conjugate vaccine era. Pediatrics 140(3):e20170181. https:\/\/doi.org\/10.1542\/peds.2017-0181","journal-title":"Pediatrics"},{"issue":"1","key":"7508_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/infdis\/160.1.83","volume":"160","author":"DW Teele","year":"1989","unstructured":"Teele DW, Klein JO, Rosner B (1989) Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 160(1):83\u201394. https:\/\/doi.org\/10.1093\/infdis\/160.1.83","journal-title":"J Infect Dis"},{"issue":"1","key":"7508_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/jpc.14105","volume":"55","author":"J Yan","year":"2019","unstructured":"Yan J, Hawes L, Turner L, Mazza D, Pearce C, Buttery J (2019) Antimicrobial prescribing for children in primary care. J Paediatr Child Health 55(1):54\u201358. https:\/\/doi.org\/10.1111\/jpc.14105","journal-title":"J Paediatr Child Health"},{"issue":"23","key":"7508_CR17","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1001\/jama.287.23.3096","volume":"287","author":"LF McCaig","year":"2002","unstructured":"McCaig LF, Besser RE, Hughes JM (2002Jun 19) Trends in antimicrobial prescribing rates for children and adolescents. JAMA 287(23):3096\u20133102. https:\/\/doi.org\/10.1001\/jama.287.23.3096. (PubMed PMID: 12069672)","journal-title":"JAMA"},{"issue":"10","key":"7508_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70179","volume":"19","author":"S Heemskerk","year":"2025","unstructured":"Heemskerk S, van Heuvel L, Spreeuwenberg P, Bont LJ, Stelma FF, Caini S et al (2025) Burden of RSV in young children in high-income countries: incidence estimates from a multilevel meta-analysis in primary and emergency care. Influenza Other Respir Viruses 19(10):e70179. https:\/\/doi.org\/10.1111\/irv.70179","journal-title":"Influenza Other Respir Viruses"},{"issue":"5","key":"7508_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13145","volume":"17","author":"Y Duan","year":"2023","unstructured":"Duan Y, Jiang M, Huang Q, Jia M, Yang W, Feng L (2023) Incidence, hospitalization, and mortality in children aged 5\u2009years and younger with respiratory syncytial virus-related diseases: a systematic review and meta-analysis. Influenza Other Respir Viruses 17(5):e13145. https:\/\/doi.org\/10.1111\/irv.13145","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"7508_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1473-3099(24)00430-4","volume":"25","author":"GBD 2021 Upper Respiratory Infections Otitis Media Collaborators","year":"2025","unstructured":"GBD 2021 Upper Respiratory Infections Otitis Media Collaborators (2025) Global, regional, and national burden of upper respiratory infections and otitis media, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis 25(1):36\u201351. https:\/\/doi.org\/10.1016\/S1473-3099(24)00430-4","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"7508_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1542\/peds.2010-2092","volume":"127","author":"W Murk","year":"2011","unstructured":"Murk W, Risnes KR, Bracken MB (2011) Prenatal or early-life exposure to antibiotics and risk of childhood asthma: a systematic review. Pediatrics 127(6):1125\u20131138. https:\/\/doi.org\/10.1542\/peds.2010-2092","journal-title":"Pediatrics"},{"issue":"6","key":"7508_CR22","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1111\/dom.13230","volume":"20","author":"SH Rasmussen","year":"2018","unstructured":"Rasmussen SH, Shrestha S, Bjerregaard LG, \u00c4ngquist LH, Baker JL, Jess T et al (2018) Antibiotic exposure in early life and childhood overweight and obesity: a systematic review and meta-analysis. Diabetes Obes Metab 20(6):1508\u20131514. https:\/\/doi.org\/10.1111\/dom.13230","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"7508_CR23","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/cid\/ciaf564","volume":"82","author":"I Fafi","year":"2026","unstructured":"Fafi I, Levy C, Birgy A, Bechet S, Werner A, Batard C et al (2026) Impact of respiratory syncytial virus immunization on the rate of pediatric acute otitis media: a time-series analysis. Clin Infect Dis 82(4):658\u2013664. https:\/\/doi.org\/10.1093\/cid\/ciaf564","journal-title":"Clin Infect Dis"},{"key":"7508_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2026.115067","volume":"294","author":"L Lenglart","year":"2026","unstructured":"Lenglart L, Levy C, Batard C, Delobbe JF, Lecailler F, B\u00e9chet S et al (2026) Effectiveness of nirsevimab on primary care visits for respiratory syncytial virus-associated acute otitis media in infants. J Pediatr 294:115067. https:\/\/doi.org\/10.1016\/j.jpeds.2026.115067","journal-title":"J Pediatr"},{"issue":"5","key":"7508_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1473-3099(25)00742-X","volume":"26","author":"JL Razzini","year":"2026","unstructured":"Razzini JL, Gin\u00e9-V\u00e1zquez I, Jin J, Santiago-P\u00e9rez MI, P\u00e9rez-Mart\u00ednez O, Otero-Barr\u00f3s MT et al (2026) Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study. Lancet Infect Dis 26(5):522\u2013534. https:\/\/doi.org\/10.1016\/S1473-3099(25)00742-X","journal-title":"Lancet Infect Dis"},{"key":"7508_CR26","unstructured":"Heikkinen T, Koskenvuo M, Peltola V (2026) Vastasyntyneille annettu nirsevimabi v\u00e4hensi tehokkaasti RSV:st\u00e4 johtuvia sairaalahoitoja. Suom L\u00e4\u00e4k\u00e4ril 81:e48219.\u00a0www.laakarilehti.fi\/e48219"},{"key":"7508_CR27","unstructured":"Summary nirsevimab [Internet]. [cited 2026 Sep 26]. Available from: https:\/\/palveluvalikoima.fi\/documents\/1237350\/261436788\/Summary_nirsevimab.pdf\/37549d10-4940-8955-0646-5e80b3b33d95?t=1778420835762"},{"issue":"5","key":"7508_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050470","volume":"13","author":"PP Wu","year":"2025","unstructured":"Wu PP, Ding FR (2025) Administration of nirsevimab for RSV prophylaxis in infants: a comprehensive review. Vaccines (Basel) 13(5):470. https:\/\/doi.org\/10.3390\/vaccines13050470","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"7508_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamapediatrics.2025.5280","volume":"180","author":"DM Sumsuzzman","year":"2026","unstructured":"Sumsuzzman DM, Shi C, Langley JM, Moghadas SM (2026) Nirsevimab against hospitalizations and emergency department visits for lower respiratory tract infection in infants: a meta-analysis. JAMA Pediatr 180(2):152\u2013159. https:\/\/doi.org\/10.1001\/jamapediatrics.2025.5280","journal-title":"JAMA Pediatr"},{"issue":"1","key":"7508_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-025-02184-4","volume":"52","author":"MS Sayed","year":"2025","unstructured":"Sayed MS, Elgendy MA, Gamil N, Abdullah HH, Alhwary A, Ibrahim RA et al (2025) Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis. Ital J Pediatr 52(1):15. https:\/\/doi.org\/10.1186\/s13052-025-02184-4","journal-title":"Ital J Pediatr"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07508-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07508-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07508-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:10:42Z","timestamp":1791583842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-07508-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7508"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07508-y","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"28 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"827"}}